FDA eGFR Readout Backs a Speculative Long on Vera Therapeutics
Vera Therapeutics' recent regulatory win and underlying kidney function data create a buyable dip for traders willing to accept biotech execution and commercial risks. Market cap near $2.3B prices in success, but short interest, healthy liquidity and an improving technical setup make a defined-risk long trade attractive over a mid-term horizon.